Longevity Health Holdings 주식 (NASDAQ: XAGEW)

에 대한 최신 뉴스 Longevity Health Holdings (NASDAQ:XAGEW) 주식

Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.

Longevity Health Holdings, Inc. - Warrant

Longevity Health Holdings Inc

Barclays analyst Ramsey El-Assal maintains Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) with a Underweight and raises the price target from $7 to $10.

News

Price Target

Analyst Ratings

GDOT

Barclays Maintains Underweight on Green Dot, Raises Price Target to $10

Barclays analyst Julian Mitchell maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Overweight and raises the price target from $22 to $23.

GTES

Barclays Maintains Overweight on Gates Industrial Corp, Raises Price Target to $23

B of A Securities analyst Derek Hewett maintains Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) with a Buy and lowers the price target from $16.5 to $15.5.

GBDC

B of A Securities Maintains Buy on Golub Capital BDC, Lowers Price Target to $15.5

Barclays analyst Adrienne Yih maintains Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Overweight and lowers the price target from $24 to $14.

Barclays Maintains Overweight on Foot Locker, Lowers Price Target to $14

WIIM

PSNY

PSNY stock has given up its prior gain. Polestar Automotive Holding shares were trading higher after the company reported a year-over-year increase in Q1 retail sales results.

B of A Securities analyst Ken Hoexter maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Neutral and raises the price target from $30 to $31.

B of A Securities Maintains Neutral on CSX, Raises Price Target to $31

Guggenheim analyst John Heinbockel reiterates US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) with a Buy and maintains $80 price target.

Reiteration

USFD

Guggenheim Reiterates Buy on US Foods Hldg, Maintains $80 Price Target

<a href="https://www.youtube.com/watch?v=u9kS0t0jkJs" title="https://www.youtube.com/watch?v=u9kS0t0jkJs">https://www.youtube.com/watch?v=u9kS0t0jkJs</a>

Biotech

Macro Economic Events

Global

Economics

General

President Trump Signs Executive Order On Drug Prices; Says European Union Has Been Brutal On Drug Prices; Will No Longer Tolerate Profiteering From Big Pharma; EU Was Most Difficult On Drug Subsidies; Brought Up Weight Loss Drugs With Drug Companies

Barclays analyst Benjamin Theurer maintains Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) with a Equal-Weight and raises the price target from $102 to $108.

Fomento Economico Mexicano S.A.B. De C.V.

Barclays Maintains Equal-Weight on Fomento Economico, Raises Price Target to $108

GOLD

PAAS

Shares of precious metals stocks are trading lower as gold and silver drop after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

FTRE

FTRE stock has given up its prior gain. Fortrea Holdings shares were trading higher after the company reported better-than-expected Q1 financial results.

B of A Securities analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Neutral and lowers the price target from $47 to $44.

KYMR

B of A Securities Maintains Neutral on Kymera Therapeutics, Lowers Price Target to $44

Barclays analyst Ryan Macwilliams maintains EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) with a Equal-Weight and raises the price target from $9 to $11.

EVCM

Barclays Maintains Equal-Weight on EverCommerce, Raises Price Target to $11

Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Neutral and maintains $47 price target.

SWTX

Guggenheim Reiterates Neutral on SpringWorks Therapeutics, Maintains $47 Price Target

Gold and silver are trading lower after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and raises the price target from $200 to $215.

EPAM

Barclays Maintains Overweight on EPAM Systems, Raises Price Target to $215

<a href="https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.">https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.</a>
&nbsp;
From cutting scan times, to speeding workflow and improving image quality, Philips is already empowering healthcare providers with AI-powered solutions to deliver faster, more accurate diagnoses for their patients [1]. Today at a major industry gathering <a href="https://www.usa.philips.com/healthcare/event/upcoming/ismrm-2025">ISMRM</a>, the company announced a new breakthrough collaboration with NVIDIA to harness cutting-edge advances in AI for MR imaging.
 &nbsp;

NVDA

Reported Earlier: 'Philips Collaborates With NVIDIA To Improve Patient Care In MR With Latest AI Advances' - Phillips

Guggenheim analyst John Heinbockel reiterates Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) with a Buy and maintains $13 price target.

Comments

Longevity Health Holdings

뉴스

에 대한 최신 뉴스 Longevity Health Holdings (NASDAQ:XAGEW) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌